PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15825995

[Hyperthyroidism: current concepts and management].

Jean-Louis Wemeau
View original source ↗Export metadata ↓

Abstract

Hyperthyroidism leads to an overproduction of thyroid hormones, which determine diverse expressions of thyrotoxicosis. However a high prevalence of mild and subclinical forms of hyperthyroidism are now recognised, since the biological measurement of thyroid hormones and TSH modified the diagnostic criteria. Clinical, biological, ultrasonographic and scintigraphic data allow the identification of the different causes of hyperthyroidism. This point is very important to assess the prognosis and to choose the right therapy. Graves' disease, solitary and multinodular toxic goiters constitute the main causes of hyperthyroidism, with iatrogenic thyrotoxicosis. Antithyroid drugs, surgery and radioactive iodine, are useful for the traditional forms of hyperthyroidism. But the choice of the therapy and the procedures for the follow-up has now a more rational background.

Explore related subjects

Antithyroid AgentsHumansHyperthyroidismIodine RadioisotopesPrevalenceThyroidectomyEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jean-Louis Wemeau. 2005-01-31. [Hyperthyroidism: current concepts and management].. https://pubmed.ncbi.nlm.nih.gov/15825995/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

L-thyroxin treatment in infants with hyperthyrotropinaemia: 4-year experience.

Hyperthyrotropinaemia, in which normal levels of T4 occur in association with raised thyroid stimulating hormone (TSH), is usually picked up on neonatal screening. High TSH level can continue for a long time in some of the cases. There is no consensus concerning the follow-up or treatment plan for hyperthyrotropinaemia. In this study, results of a 4-year follow-up of 36 cases who had been medically treated are discussed. Low-dose (5 microg/kg/day) L-thyroxin treatment was carried out in 36 cases that had 5 mU/l or higher TSH and showed exaggerated response to TRH test. Dose was decreased to 2-3 microg/kg/day in 24 of these patients during 6 months follow-up. The drug was stopped in three cases because of the development of biochemical hyperthyroidism. Denver developmental assessment test was applied to all cases at the end of the third year. All patients showed a normal development in relation to their age. According to our results, cases with hyperthyrotropinaemia need to be followed regularly for a long time and a need for low-dose L-thyroxin treatment may exist at ages varying from patient to patient.

Antithyroid Agents↗
PubMed2006

Synthesis and structures of Se analogues of the antithyroid drug 6-n-propyl-2-thiouracil and its alkyl derivatives: formation of dimeric Se-Se compounds and deselenation reactions of charge-transfer adducts of diiodine.

Four selenium analogues of the antithyroid drug 6-n-propyl-2-thiouracil (PTU), of formulae RSeU, (R = methyl (Me) (1), ethyl (Et) (2), n-propyl (nPr) (3), and isopropyl (iPr) 4), have been synthesized. Reaction of 1-4 with diiodine in a 1:1 molar ratio in dichloromethane results in the formation of [(RSeU)I(2)] (R = methyl (5), ethyl (6), n-propyl (7) and isopropyl (8)). All compounds have been characterized by elemental analysis, FT-Raman, FT-IR, UV/Vis, (1)H-, (13)C-, (77)Se-1D and -2D NMR spectroscopy, and ESI-MS spectrometric techniques. Recrystallization of 4 from dichloromethane afforded (4CH(2)Cl(2)). Crystals of [(nPrSeU)I(2)] (7), a charge-transfer complex, were obtained from chloroform solutions, while crystallization of 6 and 7 from acetone afforded the diselenides [N-(6-Et-4-pyrimidone)(6-EtSeU)(2)] (92 H(2)O) and [N-(6-nPr-4-pyrimidone)(6-nPrSeU)(2)] (10) as oxidation products. Recrystallization of 7 from methanol/acetonitrile solutions led to deselenation with the formation of 6-n-propyl-2-uracil (nPrU) (11). [(nPrSeU)I(2)] (7) was found to be a charge-transfer complex with a Se--I bond. These results are discussed in relation to the mechanism of action of antithyroid drugs.

Antithyroid Agents↗
PubMed2006

[Hyperthyroidism].

Although the classical presentation of hyperthyroidism is known from the nineteenth century, the mindful evaluation of the clinical symptoms is indispensable for the practitioner physician. The clinical picture depends on the etiology of hyperthyroidism, the gender and age of the patient. The methods for the laboratory diagnosis of hyperthyroidism have outstanding accuracy, the supersensitive TSH, free thyroxine and triiodothyronine determinations are generally available. The etiology of hyperthyroidism was broadened by new diseases: gestational hyperthyroidism caused by human choriogonadotropin and the group of congenital non-autoimmune hyperthyroidism due to TSH receptor mutations were discovered. The iodine-induced hyperthyroidism, which is an everyday problem due to the widespread use of amiodarone treatment, is also better characterized. The role of different treatment modalities in the therapeutic algorithm was established, the part of surgery decreased. The optimal duration and dose of drug treatment in Graves' disease is still questionable in the lack of good evidence, nowadays one and half year of antithyroid treatment is generally recommended. The reduction of relapse rate below 50% after the discontinuation of antithyroid drug was unsuccessful, risk factors are the large goiter, elevated level of the TSH receptor antibodies, in certain studies the male gender and young age. Due to the high relapse rate, the radioiodine treatment is preferred, even as a primary therapy. In case of toxic adenoma, toxic multinodular goiter and congenital non-autoimmune hyperthyroidism the medical treatment cannot result in permanent cure, therefore primary ablative treatment is required. The chances of patients with hyperthyroidism for the complete recovery are excellent, however, long time follow-up is necessary.

Antithyroid Agents↗